Shanghai Haohai Biological Technology Co. Ltd Asset Resilience Ratio
Shanghai Haohai Biological Technology Co. Ltd asset resilience ratio. Shanghai Haohai Biological Technology Co. Ltd (5HB) has an Asset Resilience Ratio of 1.13% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Shanghai Haohai Biological Technology Co fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shanghai Haohai Biological Technology Co. Ltd (2018–2025)
Asset resilience ratio of Shanghai Haohai Biological Technology Co. Ltd from 2018 to 2025. This chart shows how Shanghai Haohai Biological Technology Co. Ltd's Asset Resilience Ratio has changed over time. Read Shanghai Haohai Biological Technology Co balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Haohai Biological Technology Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 5HB current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €76.11 Million | 1.13% |
| Total Liquid Assets | €76.11 Million | 1.13% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Haohai Biological Technology Co. Ltd maintains only 1.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Haohai Biological Technology Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Haohai Biological Technology Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Shanghai Haohai Biological Technology Co. Ltd Asset Resilience Ratio by Year (2018–2025)
Shanghai Haohai Biological Technology Co. Ltd asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Shanghai Haohai Biological Technology Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.13% | €76.11 Million ≈ $88.98 Million |
€6.72 Billion ≈ $7.86 Billion |
-0.10pp |
| 2024-12-31 | 1.23% | €87.85 Million ≈ $102.70 Million |
€7.12 Billion ≈ $8.33 Billion |
+1.08pp |
| 2023-12-31 | 0.16% | €11.08 Million ≈ $12.96 Million |
€7.11 Billion ≈ $8.31 Billion |
+0.06pp |
| 2022-12-31 | 0.10% | €6.75 Million ≈ $7.89 Million |
€6.89 Billion ≈ $8.06 Billion |
+0.01pp |
| 2021-12-31 | 0.09% | €6.38 Million ≈ $7.45 Million |
€6.95 Billion ≈ $8.13 Billion |
-0.15pp |
| 2020-12-31 | 0.24% | €15.14 Million ≈ $17.71 Million |
€6.30 Billion ≈ $7.36 Billion |
-1.59pp |
| 2018-12-31 | 1.83% | €81.28 Million ≈ $95.03 Million |
€4.44 Billion ≈ $5.19 Billion |
-- |
About Shanghai Haohai Biological Technology Co. Ltd
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and ot… Read more